ClinicalTrials.gg
CompletedNCT00415532Updated Nov 8, 2022Results posted

Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura

A Phase 3 interventional study of Medical Standard of Care for ITP and Romiplostim in Idiopathic Thrombocytopenic Purpura, Thrombocytopenia and Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
4th of 29
234 · median 62
Started
2006
with 1 other
Phase 3
13 of 29
1 open now
Registered
7th of 29
by date
Lead sponsor
14 of 29
Amgen

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 4th largest by enrollment, is one of 2 that started in 2006, is one of 13 in phase 3, and was the 7th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label, 52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia Purpura (ITP), with a 6-month Safety Follow-up. Patients randomized to romiplostim must complete the taper or discontinuation of medical SOC for ITP as soon as medically feasible after the initiation of romiplostim. After the completion or discontinuation of the study treatment period, any participant who does not transfer in to another romiplostim study will complete a 6-month Safety Follow-up period.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura
  • Thrombocytopenia
  • Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
  • Thrombocytopenic Purpura

Keywords

  • splenectomy
  • platelet
  • AMG 531
  • thrombopoietin
  • blood disorder
  • bleeding disorder
  • immune thrombocytopenic purpura
  • idiopathic thrombocytopenic purpura
  • immune (idiopathic) thrombocytopenic purpura
  • TPO
  • thrombopoietic protein
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥ 18 years of age
  • Subject has a diagnosis of Idiopathic Thrombocytopenia Purpura (ITP) according to the American Society of Hematology (ASH) guidelines
  • If subject is > 60 years of age, subject has a written bone marrow report confirming the diagnosis of ITP
  • Subject has received at least 1 prior therapy for ITP
  • Subject has a count \< 50,000 or their platelet count falls to \< 50,000 during or after a clinically-indicated taper or discontinuation of current ITP therapy
  • Before any study-specific procedure, the appropriate written must be obtained

Exclusion criteria

Exclusion Criteria:

  • Subject has had a splenectomy for any reason
  • Subject has an active
  • Subject has a history of cancer, other than basal cell carcinoma or cervical carcinoma in situ, with treatment or active disease within 5 years
  • Subject has a known history of bone marrow stem cell disorder
  • Subject has participated in any study evaluating polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO), AMG 531, or a thrombopoietic protein
  • Subject is receiving other agents or procedures
  • Subject is currently enrolled in, or has completed within the last 30 days, another investigational device or drug study
  • Subject is pregnant or breast feeding
  • Subject is not using adequate precautions
  • Subject has known sensitivity to any recombinant E. coli-derived product
  • Subject has any kind of disorder that compromises the ability of the subject to give written and does not have a legally acceptable representative
  • Subject has any kind of disorder that compromises the ability of the subject to comply with study procedures
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
234 participants (actual)

Study arms

  • Experimental
    Romiplostim

    Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10\^9/L for up to 52 weeks.

    Biological: Romiplostim

  • Other
    Standard of Care

    Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.

    Drug: Medical Standard of Care for ITP

Interventions

  • DrugMedical Standard of Care for ITP
  • BiologicalRomiplostim

    Also known as: AMG 531

06

What researchers measure

Primary outcomes

  1. Number of Participants With Splenectomy During 52-Week Treatment Period

    Occurrence of a splenectomy. Participants who discontinued study during the treatment period prior to reporting a splenectomy were considered as having had a splenectomy.

    Time frame: 52 weeks

  2. Number of Participants With Treatment Failure During 52-Week Treatment Period

    Treatment failure was defined by platelet counts ≤ 20 x 10\^9/L for 4 consecutive weeks at the highest recommended dose and schedule, a major bleeding event, or change in therapy due to an intolerable side effect or bleeding symptom.

    Time frame: 52 weeks

Secondary outcomes

  1. Time to Splenectomy

    Time to splenectomy in days calculated from date of randomization to date of splenectomy, or censored at date of end of treatment visit if no splenectomy was done during treatment period.

    Time frame: 52 weeks

  2. Percentage of Participants With Platelet Response

    Platelet response was defined as platelet counts \> 50 x 10\^9/L, measured at each study visit (excluding those within 8 weeks of prior rescue medication use) up to the time of splenectomy or the end of initial treatment period, whichever occurred first.

    Time frame: Weeks 1-8, and Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

  3. Change in ITP-PAQ Physical Health Domain of Symptoms

    Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of symptoms. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.

    Time frame: Baseline and 52 weeks

  4. Change in ITP-PAQ Physical Health Domain of Fatigue

    Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of fatigue. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.

    Time frame: Baseline and 52 weeks

  5. Change in ITP-PAQ Physical Health Domain of Bother

    Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of bother. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.

    Time frame: Baseline and 52 weeks

  6. Change in ITP-PAQ Physical Health Domain of Activity

    Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of activity. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.

    Time frame: Baseline and 52 weeks

07

Results

Posted Jul 8, 2013

Participant flow

First Subject Enrolled: 20-Dec-2006 Last Subject Enrolled: 01-Nov-2007

Treatment Period
Participant flow — Treatment Period
MilestoneStandard of CareRomiplostim
Started77157
Received treatment75154
Switched to romiplostim group20
Completed60142
Not completed1715
Withdrew: Adverse event23
Withdrew: Death21
Withdrew: Lost to follow-up11
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject66
Withdrew: Other22
Withdrew: Ineligibility determined11
Withdrew: Noncompliance11
Withdrew: Requirement for alternative therapy10
Safety Follow Up Period
Participant flow — Safety Follow Up Period
MilestoneStandard of CareRomiplostim
Started4330
Completed3418
Not completed912
Withdrew: Adverse event13
Withdrew: Death30
Withdrew: Withdrawal by subject23
Withdrew: Other14
Withdrew: Ineligibility determined11
Withdrew: Noncompliance10
Withdrew: Requirement for alternative therapy01

Outcome measures

PrimaryNumber of Participants With Splenectomy During 52-Week Treatment Period

Occurrence of a splenectomy. Participants who discontinued study during the treatment period prior to reporting a splenectomy were considered as having had a splenectomy.

Time frame:
52 weeks
Reported as:
Number · Participants
Number of Participants With Splenectomy During 52-Week Treatment Period
ParticipantsStandard of CareRomiplostim
Had splenectomy2814
Did not have splenectomy49143
Statistical analysis
  • Standard of Care vs Romiplostim · Cochran-Mantel-Haenszel · p = <0.0001 (Significant level is set at 0.05) · Odds ratio (or): 0.172 · 95% CI 0.084 to 0.352
PrimaryNumber of Participants With Treatment Failure During 52-Week Treatment Period

Treatment failure was defined by platelet counts ≤ 20 x 10\^9/L for 4 consecutive weeks at the highest recommended dose and schedule, a major bleeding event, or change in therapy due to an intolerable side effect or bleeding symptom.

Time frame:
52 weeks
Reported as:
Number · Participants
Number of Participants With Treatment Failure During 52-Week Treatment Period
ParticipantsStandard of CareRomiplostim
Had treatment failure2318
Did not have treatment failure54139
Statistical analysis
  • Standard of Care vs Romiplostim · Cochran-Mantel-Haenszel · p = 0.0005 (Significant level is set at 0.05) · Odds ratio (or): 0.307 · 95% CI 0.154 to 0.611
SecondaryTime to Splenectomy

Time to splenectomy in days calculated from date of randomization to date of splenectomy, or censored at date of end of treatment visit if no splenectomy was done during treatment period.

Time frame:
52 weeks
Reported as:
Median · days
Time to Splenectomy
daysStandard of CareRomiplostim
Time to SplenectomyNA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With Platelet Response

Platelet response was defined as platelet counts \> 50 x 10\^9/L, measured at each study visit (excluding those within 8 weeks of prior rescue medication use) up to the time of splenectomy or the end of initial treatment period, whichever occurred first.

Time frame:
Weeks 1-8, and Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Platelet Response
percentage of participantsStandard of CareRomiplostim
Week 1 [N=75, 154]6.73.9
Week 2 [N=71, 153]28.275.8
Week 3 [N=70, 152]34.373.0
Week 4 [N=170, 152]30.073.7
Week 5 [N=68, 152]32.471.1
Week 6 [N=66, 151]30.374.2
Week 7 [N=66, 151]30.375.5
Week 8 [N=65, 151]29.268.2
Week 12 [N=62, 149]25.879.2
Week 16 [N=61, 147]34.482.3
Week 20 [N=58, 139]36.283.5
Week 24 [N=58, 138]31.092.0
Week 28 [N=57, 137]40.488.3
Week 32 [N=55, 135]34.587.4
Week 36 [N=54, 135]33.389.6
Week 40 [N=52, 134]38.588.8
Week 44 [N=51, 131]51.086.3
Week 48 [N=48, 130]41.788.5
Week 52 [N=38, 122]50.090.2
SecondaryChange in ITP-PAQ Physical Health Domain of Symptoms

Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of symptoms. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.

Time frame:
Baseline and 52 weeks
Reported as:
Least squares mean · Units on a scale
Change in ITP-PAQ Physical Health Domain of Symptoms
Units on a scaleStandard of CareRomiplostim
Change in ITP-PAQ Physical Health Domain of Symptoms12.5 ± 2.116.0 ± 1.9
Statistical analysis
  • Standard of Care vs Romiplostim · Mixed Models Analysis · p = 0.0133 (Significant level is set at 0.05)
SecondaryChange in ITP-PAQ Physical Health Domain of Fatigue

Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of fatigue. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.

Time frame:
Baseline and 52 weeks
Reported as:
Least squares mean · Units on a scale
Change in ITP-PAQ Physical Health Domain of Fatigue
Units on a scaleStandard of CareRomiplostim
Change in ITP-PAQ Physical Health Domain of Fatigue9.5 ± 3.211.2 ± 3.1
Statistical analysis
  • Standard of Care vs Romiplostim · Mixed Models Analysis · p = 0.3434 (Significant level is set at 0.05)
SecondaryChange in ITP-PAQ Physical Health Domain of Bother

Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of bother. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.

Time frame:
Baseline and 52 weeks
Reported as:
Least squares mean · Units on a scale
Change in ITP-PAQ Physical Health Domain of Bother
Units on a scaleStandard of CareRomiplostim
Change in ITP-PAQ Physical Health Domain of Bother13.0 ± 2.716.8 ± 2.5
Statistical analysis
  • Standard of Care vs Romiplostim · Mixed Models Analysis · p = 0.0076 (Significant level is set at 0.05)
SecondaryChange in ITP-PAQ Physical Health Domain of Activity

Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of activity. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.

Time frame:
Baseline and 52 weeks
Reported as:
Least squares mean · Units on a scale
Change in ITP-PAQ Physical Health Domain of Activity
Units on a scaleStandard of CareRomiplostim
Change in ITP-PAQ Physical Health Domain of Activity8.2 ± 3.717.1 ± 3.5
Statistical analysis
  • Standard of Care vs Romiplostim · Mixed Models Analysis · p = 0.0246 (Significant level is set at 0.05)

Adverse events

Collected over 52 week treatment period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard of Care—28/73 (38.4%)60/73 (82.2%)
AMG 531—36/156 (23.1%)136/156 (87.2%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventStandard of CareAMG 531
ThrombocytopeniaBlood and lymphatic system disorders8/736/156
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders3/730/156
Abdominal painGastrointestinal disorders2/731/156
PneumoniaInfections and infestations2/734/156
Oedema peripheralGeneral disorders0/733/156
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/733/156
CoagulopathyBlood and lymphatic system disorders1/730/156
ArrhythmiaCardiac disorders1/730/156
Atrial fibrillationCardiac disorders1/730/156
Cardiac failure congestiveCardiac disorders1/730/156
Most frequent other events
Showing 10 of 48
Most frequent other events
EventStandard of CareAMG 531
HeadacheNervous system disorders14/7354/156
FatigueGeneral disorders16/7343/156
EpistaxisRespiratory, thoracic and mediastinal disorders17/7329/156
NasopharyngitisInfections and infestations14/7336/156
ContusionInjury, poisoning and procedural complications13/7322/156
PetechiaeSkin and subcutaneous tissue disorders13/7325/156
CoughRespiratory, thoracic and mediastinal disorders4/7325/156
NauseaGastrointestinal disorders6/7324/156
ArthralgiaMusculoskeletal and connective tissue disorders4/7323/156
DiarrhoeaGastrointestinal disorders4/7321/156

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Standard of CareRomiplostimTotal
Mean54.7 ± 19.354.8 ± 18.854.7 ± 18.9
Sex: Female, Male
Sex: Female, Male(Participants)Standard of CareRomiplostimTotal
Female4685131
Male3172103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Standard of CareRomiplostimTotal
White or Caucasian69137206
Black or African American066
Hispanic or Latino5914
Asian (Chinese, Bangladeshi, Indian, Pakistani)156
American Indian or Alaska Native101
Other101
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kuter DJ, Mathias SD, Rummel M, Mandanas R, Giagounidis AA, Wang X, Deuson RR. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol. 2012 May;87(5):558-61. doi: 10.1002/ajh.23163. Epub 2012 Mar 28. PubMed 22460421 ↗
  • Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010 Nov 11;363(20):1889-99. doi: 10.1056/NEJMoa1002625. PubMed 21067381 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2006 to primary completion in Nov 2008, 23 months.

Results were first posted in Jul 2013, 4 years 8 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 23 months is close to that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2006
First posted
Dec 25, 2006
StartActual
Dec 1, 2006
Primary completionActual
Nov 7, 2008
CompletionActual
May 11, 2009
Results first posted
Jul 8, 2013
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00415532
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 25, 2006
Start date
Dec 1, 2006
Primary completion
Nov 7, 2008
Completion
May 11, 2009
Results posted
Jul 8, 2013
Last update
Nov 8, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion